Spyre Therapeutics (SYRE) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Spyre Therapeutics is expected to report Q3 2026 results after Tuesday’s market close, with analysts forecasting a loss of $0.7807 per share. The company previously beat consensus estimates by $0.40 per share in Q2.
• Shares opened at $92.91, up 2.9%, and have risen significantly from the 12-month low of $21.15. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $110.40.
• Company insiders have recently sold shares, including the CEO and CFO under pre-arranged Rule 10b5-1 plans; insiders sold 183,564 shares worth about $16.9 million over the past three months.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.7807) per share for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.40. On average, analysts expect Spyre Therapeutics to post ($2.71) EPS for the current fiscal year and ($3.67) EPS for the next fiscal year.

Spyre Therapeutics Stock Up 2.9%

Shares of SYRE opened at $92.91 on Tuesday. The business's fifty day moving average is $90.75 and its 200 day moving average is $71.50. Spyre Therapeutics has a 12-month low of $21.15 and a 12-month high of $110.18. The stock has a market cap of $9.47 billion, a P/E ratio of -47.65 and a beta of 3.10.

Insider Buying and Selling

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $92.01, for a total transaction of $1,380,150.00. Following the transaction, the chief executive officer directly owned 537,540 shares in the company, valued at approximately $49,459,055.40. This trade represents a 2.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of Spyre Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $91.83, for a total transaction of $688,725.00. Following the transaction, the chief financial officer directly owned 79,762 shares in the company, valued at $7,324,544.46. This represents a 8.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 183,564 shares of company stock worth $16,903,193. 15.69% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

SYRE has been the topic of several research reports. Guggenheim upped their price objective on shares of Spyre Therapeutics from $115.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Wolfe Research cut shares of Spyre Therapeutics from an "outperform" rating to a "peer perform" rating in a report on Tuesday, July 28th. BTIG Research reissued a "buy" rating and set a $121.00 target price on shares of Spyre Therapeutics in a research report on Monday, October 19th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Spyre Therapeutics from $135.00 to $127.00 and set a "buy" rating on the stock in a report on Wednesday, August 26th. Finally, Mizuho upped their target price on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $110.40.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The company's approach is centered on engineered antibody therapies designed to provide durable disease control, convenient dosing and improved treatment characteristics.

Spyre's investigational pipeline includes antibody programs directed at important inflammatory pathways, including interleukin-23 (IL-23) and TL1A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.